Archived explainer. For the current picture see today's CDNA page.
CAREDX INC (CDNA) is up +35.60% in the latest session. Our newswire has captured 6 stories on CDNA across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100).
CareDx Inc. (CDNA) surged by 35.60% to $40.34 in a single session, driven by the finalization of Medicare coverage for its molecular transplant surveillance tests. The policy change, which grants broad coverage for kidney, heart, and lung transplant monitoring services, has generated optimism about the company’s long-term revenue potential. The stock opened with a 2.7% gap and climbed steadily throughout the session, peaking at $40.38 before settling near the high.
Medicare finalized a Local Coverage Determination (LCD) that confirms reimbursement for CareDx’s molecular tests used in monitoring solid organ transplants. The policy, which becomes effective on August 30, allows up to six tests in the first year and four annually in years two and three. This development provides increased clarity and stability for CareDx, which has been working to expand its market reach in the transplant surveillance space. The news was widely reported and contributed to a rally in the stock, with shares jumping as much as 18% in early coverage.
The CEO of CareDx, John Walter, has sold shares in recent weeks, with two transactions reported in June 2026. Additionally, a director, Hannah Valantine, also sold shares on June 15. These insider sales occurred before the Medicare announcement and do not appear to have influenced the stock’s recent move.
The stock opened at $30.55 and climbed to a session high of $40.38, with volume reaching 3.7 million shares, nearly 4.8 times the 3-month average. The move pushed the stock beyond its 52-week high of $30.00, reaching a new peak of $40.38. CareDx remains unprofitable, with a trailing 12-month net loss and a market cap of $1.5 billion. The stock has a beta of 2.43, indicating it is more volatile than the broader market.
CareDx is scheduled to report its second quarter 2026 financial results on July 30, 2026. The upcoming earnings release will provide insight into how the Medicare coverage change is already impacting revenue and customer adoption. Investors will also monitor the stock’s performance in the coming weeks for signs of continued momentum or profit-taking.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
CareDx, Inc. will reveal its second quarter 2026 financial results on July 30, drawing investor attention after a sharp 23.9% move in the stock. The article unpacks what the pre-announcement means for market sentiment, outlines key event information, and explores the broader significance for precision medicine investors.
CareDx shares surged after Medicare finalized coverage for its molecular transplant surveillance tests, confirming reimbursement across kidney, heart and lung transplant monitoring services.
CareDx (CDNA) stock jumps 18% after Medicare finalizes LCD coverage for transplant molecular tests.
The finalized Medicare Local Coverage Determination (LCD) grants comprehensive coverage for CareDx’s leading molecular surveillance tests in kidney, heart, and lung transplants, offering increased clarity and stability for patients and providers. This article examines the core coverage changes, how they align with clinical needs, and what they could mean for CareDx's future.
Results will be released after market close, followed by a 1:30 p.m. PT webcast and conference call; CareDx will provide live and archived access online.
Kidney rejection-surveillance coverage allows up to six tests in year one and four annually in years two and three; the final policy is expected to take effect Aug. 30.
More on CDNA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier CDNA move explainers: 2026-07-17 · 2026-07-16